The Pharmacokinetics of Sertraline Excretion Into Human Breast Milk: Determinants of Infant Serum Concentrations
J Clin Psychiatry 2003;64(1):73-80
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The purpose of this study was to
attain a new landmark in the area of selective serotonin reuptake
inhibitor therapy during lactation by establishing a basis for
interpreting infant serum concentrations and for minimizing
infant exposure in the absence of treatment-emergent side
Method: Breast milk and paired maternal and
infant sera were collected following maternal treatment with
sertraline monotherapy (25-200 mg/day) administered once daily.
Sertraline and its major metabolite were measured in breast milk
and serum samples using high-performance liquid chromatography
with UV detection (limit of detection=2 ng/mL).
Results: Twenty-six nursing women with DSM-IV major depressive disorder participated in the study; the mean (SD) daily sertraline dose was 123.9 (62.8) mg/day. Fifteen women submitted 182 breast milk samples for analysis of gradient (foremilk to hindmilk) and time course of medication excretion. The milk/plasma ratio was highly variable (range, 0.42–4.81). A significant gradient and time course of excretion for both sertraline (p < .001 for both) and desmethylsertraline (p < .001 for gradient and p < .046 for time course) were observed, with the highest concentrations observed in the hindmilk 8 to 9 hours after maternal ingestion. Mathematical modeling of sertraline and desmethylsertraline excretion revealed that discarding breast milk 9 hours after maternal dose decreased the infant daily dose of sertraline by a mean of 17.1% (1.8%). Twenty-two mother/infant sera pairs were obtained. Sertraline was detectable in 4 infants (18% of sample), and desmethylsertraline was found in 11 infants (50% of sample). The mean (SD) maximum calculated nursing infant dose of sertraline, 0.67 (0.61) mg/day, and desmethylsertraline, 1.44 (1.36) mg/day, represented 0.54% (0.49%) of the maternal daily dose. The maximum infant dose of desmethylsertraline (p < .002) significantly correlated with infant serum desmethylsertraline concentrations (ng/mL). In contrast, maternal daily dose, duration of medication exposure, and infant age and weight at sampling did not correlate with either detectability (< 2 ng/mL vs. ≥ 2 ng/mL) or absolute concentrations (ng/mL) in infant serum. No adverse events were reported or documented in any infant.
Conclusion: These results extend previous
studies by demonstrating the utility of breast milk analysis in
interpreting infant serum concentrations and minimizing infant